Development of a scalable production bioprocess for HIV-1 virus-like particles coupling continuous VLP harvesting with end-to-end downstream processing

Posted on
development-of-a-scalable-production-bioprocess-for-hiv-1-virus-like-particles-coupling-continuous-vlp-harvesting-with-end-to-end-downstream-processing
Development of a scalable production bioprocess for HIV-1 virus-like particles coupling continuous VLP harvesting with end-to-end downstream processing

References

  1. Fuenmayor, J., Gòdia, F. & Cervera, L. Production of virus-like particles for vaccines. New Biotechnol. 39, 174–180. https://doi.org/10.1016/j.nbt.2017.07.010 (2017).

    Google Scholar 

  2. Nooraei, S. et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J. Nanobiotechnology 19, 1–27 (2021).

    Google Scholar 

  3. Zuñiga, R. et al. Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control. J. Virol. 80, 3122–3125 (2006).

    Google Scholar 

  4. Lee, C. D., Yan, Y. P., Liang, S. M. & Wang, T. F. Production of FMDV virus-like particles by a SUMO fusion protein approach in Escherichia coli. J. Biomed. Sci. 16, 1–7 (2009).

    Google Scholar 

  5. Venereo-Sánchez, A. et al. Characterization of influenza H1N1 Gag virus-like particles and extracellular vesicles co-produced in HEK-293SF. Vaccine https://doi.org/10.1016/j.vaccine.2019.07.057 (2019).

    Google Scholar 

  6. Giles, B. M. & Ross, T. M. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29, 3043–3054 (2011).

    Google Scholar 

  7. Chua, A. J. et al. A novel platform for virus-like particle-display of flaviviral envelope domain III: Induction of Dengue and West Nile virus neutralizing antibodies. Virol. J. 10, 1–18 (2013).

    Google Scholar 

  8. Garnier, L. et al. Incorporation of pseudorabies virus gD into human immunodeficiency virus type 1 Gag particles produced in baculovirus-infected cells. J. Virol. 69, 4060–4068 (1995).

    Google Scholar 

  9. Fontana, D. et al. Chimeric vlps based on hiv-1 gag and a fusion rabies glycoprotein induce specific antibodies against rabies and foot-and-mouth disease virus. Vaccines https://doi.org/10.3390/vaccines9030251 (2021).

    Google Scholar 

  10. Osterrieder, N., Wagner, R., Brandmüller, C., Schmidt, P. & Wolf, H. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB). Virology 208, 500–510. https://doi.org/10.1006/viro.1995.1181 (1995).

    Google Scholar 

  11. Di Bonito, P. et al. Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 395, 45–55 (2009).

    Google Scholar 

  12. Boix-Besora, A., Lorenzo, E., Lavado-García, J., Gòdia, F. & Cervera, L. Optimization, production, purification and characterization of HIV-1 GAG-based virus-like particles functionalized with SARS-CoV-2. Vaccines (Basel). 10, 1–18 (2022).

    Google Scholar 

  13. Mohsen, M. O., Speiser, D. E., Knuth, A. & Bachmann, M. F. Virus-like particles for vaccination against cancer. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. https://doi.org/10.1002/wnan.1579 (2020).

    Google Scholar 

  14. Gutiérrez-Granados, S., Cervera, L., Kamen, A. A. & Gòdia, F. Advancements in mammalian cell transient gene expression (TGE) technology for accelerated production of biologics. Crit. Rev. Biotechnol. 38, 918–940. https://doi.org/10.1080/07388551.2017.1419459 (2018).

    Google Scholar 

  15. Bielser, J. M., Wolf, M., Souquet, J., Broly, H. & Morbidelli, M. Perfusion mammalian cell culture for recombinant protein manufacturing – A critical review. Biotechnol. Adv. 36, 1328–1340 (2018).

    Google Scholar 

  16. Lavado-García, J., Pérez-Rubio, P., Cervera, L. & Gòdia, F. The cell density effect in animal cell-based bioprocessing: Questions, insights and perspectives. Biotechnol. Adv. https://doi.org/10.1016/j.biotechadv.2022.108017 (2022).

    Google Scholar 

  17. Hong, J. et al. Development of an alternating tangential flow (ATF) perfusion-based transient gene expression (TGE) bioprocess for universal influenza vaccine. Biotechnol. Prog. https://doi.org/10.1002/btpr.2831 (2019).

    Google Scholar 

  18. Lavado-García, J., Cervera, L. & Gòdia, F. An alternative perfusion approach for the intensification of virus-like particle production in HEK293 cultures. Front. Bioeng. Biotechnol. 8, 617 (2020).

    Google Scholar 

  19. Hein, M. D. et al. Production of retroviral vectors in continuous high cell density culture. Appl. Microbiol. Biotechnol. 107, 5947–5961 (2023).

    Google Scholar 

  20. Vicente, T., Roldão, A., Peixoto, C., Carrondo, M. J. T. & Alves, P. M. Large-scale production and purification of VLP-based vaccines. J. Invertebr. Pathol. https://doi.org/10.1016/j.jip.2011.05.004 (2011).

    Google Scholar 

  21. Mittal, M., Banerjee, M., Lua, L. H. L. & Rathore, A. S. Current status and future challenges in transitioning to continuous bioprocessing of virus-like particles. J. Chem. Technol. Biotechnol. 97, 2376–2385 (2022).

    Google Scholar 

  22. Lavado-García, J. et al. Molecular characterization of the coproduced extracellular vesicles in HEK293 during virus-like particle production. J. Proteome Res. 19, 4532 (2020).

    Google Scholar 

  23. Zhao, Q., Li, S., Yu, H., Xia, N. & Modis, Y. Virus-like particle-based human vaccines: Quality assessment based on structural and functional properties. Trends Biotechnol. 31, 654–663 (2013).

    Google Scholar 

  24. Moleirinho, M. G., Silva, R. J. S., Alves, P. M., Carrondo, M. J. T. & Peixoto, C. Current challenges in biotherapeutic particles manufacturing. Expert Opin. Biol. Ther. 00, 1–15 (2019).

    Google Scholar 

  25. González-Domínguez, I. et al. A four-step purification process for gag vlps: From culture supernatant to high-purity lyophilized particles. Vaccines (Basel). 9, 1–19 (2021).

    Google Scholar 

  26. Pereira Aguilar, P. et al. Capture and purification of Human Immunodeficiency Virus-1 virus-like particles: Convective media vs porous beads. J. Chromatogr. A 1627, 1–11 (2020).

    Google Scholar 

  27. Steppert, P. et al. Separation of HIV-1 gag virus-like particles from vesicular particles impurities by hydroxyl-functionalized monoliths. J. Sep. Sci. https://doi.org/10.1002/jssc.201600765 (2017).

    Google Scholar 

  28. Steppert, P. et al. Purification of HIV-1 gag virus-like particles and separation of other extracellular particles. J. Chromatogr. A 1455, 93–101 (2016).

    Google Scholar 

  29. Lorenzo, E., Miranda, L., Gòdia, F. & Cervera, L. Downstream process design for Gag HIV-1 based virus-like particles. Biotechnol. Bioeng. 120, 2672–2684 (2023).

    Google Scholar 

  30. Roldão, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J. T. & Alves, P. M. Virus-like particles in vaccine development. Expert Rev. Vaccines 9, 1149–1176. https://doi.org/10.1586/erv.10.115 (2010).

    Google Scholar 

  31. Szabó, É., Baranyai, L. Z., Sütő, Z., Salgó, A. & Gergely, S. Attenuated total reflection fourier transform infrared spectroscopy based methods for identification of chromatography media formulations used in downstream processes. J. Pharm. Biomed. Anal. https://doi.org/10.1016/j.jpba.2019.113060 (2020).

    Google Scholar 

  32. Kumru, O. S. et al. Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies. Biologicals 42, 237–259 (2014).

    Google Scholar 

  33. Tang, X. C. & Pikal, M. J. Design of freeze-drying processes for pharmaceuticals: Practical advice. Pharm. Res. 21, 191–200 (2004).

    Google Scholar 

  34. Emami, F., Vatanara, A., Park, E. J. & Na, D. H. Drying technologies for the stability and bioavailability of biopharmaceuticals. Pharmaceutics 10, 1–22 (2018).

    Google Scholar 

  35. Lavado-García, J., Jorge, I., Cervera, L., Vázquez, J. & Gòdia, F. Multiplexed quantitative proteomic analysis of HEK293 provides insights into molecular changes associated with the cell density effect, transient transfection, and virus-like particle production. J. Proteome Res. 19, 1085–1099 (2020).

    Google Scholar 

  36. Lavado-García, J. et al. Metabolic engineering of HEK293 cells to improve transient transfection and cell budding of HIV‐1 virus‐like particles. Biotechnol. Bioeng. https://doi.org/10.1002/bit.27679 (2021).

    Google Scholar 

  37. Buffo, M. M. et al. Influence of dual-impeller type and configuration on oxygen transfer, power consumption, and shear rate in a stirred tank bioreactor. Biochem. Eng. J. 114, 130–139 (2016).

    Google Scholar 

  38. Lorenzo, E., Miranda, L., Gòdia, F. & Cervera, L. Downstream process design for Gag HIV – 1 based virus – like particles. Biotechnol. Bioeng. 120, 2672–2684 (2023).

    Google Scholar 

  39. Lavado-García, J. et al. Characterization of HIV-1 virus-like particles and determination of Gag stoichiometry for different production platforms. Biotechnol. Bioeng. 118, 2660–2675 (2021).

    Google Scholar 

  40. Cervera, L., Gutiérrez-Granados, S., Berrow, N. S., Segura, M. M. & Gòdia, F. Extended gene expression by medium exchange and repeated transient transfection for recombinant protein production enhancement. Biotechnol. Bioeng. 112, 934–946 (2015).

    Google Scholar 

  41. Nikolay, A., de Grooth, J., Genzel, Y., Wood, J. A. & Reichl, U. Virus harvesting in perfusion culture: Choosing the right type of hollow fiber membrane. Biotechnol. Bioeng. 117, 3040–3052 (2020).

    Google Scholar 

  42. Gutiérrez-Granados, S., Gòdia, F. & Cervera, L. Continuous manufacturing of viral particles. Curr. Opin. Chem. Eng. 22, 107–114 (2018).

    Google Scholar 

  43. Carvalho, S. B. et al. Efficient filtration strategies for the clarification of influenza virus-like particles derived from insect cells. Sep. Purif. Technol. 218, 81–88 (2019).

    Google Scholar 

  44. Lan, N. T. et al. Stability of virus-like particles of red-spotted grouper nervous necrosis virus in the aqueous state, and the vaccine potential of lyophilized particles. Biologicals 51, 25–31 (2018).

    Google Scholar 

  45. Comisel, R. M., Kara, B., Fiesser, F. H. & Farid, S. S. Lentiviral vector bioprocess economics for cell and gene therapy commercialization. Biochem. Eng. J. 167, 107868 (2021).

    Google Scholar 

  46. Hein, M. D. et al. Cell culture–based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system. Appl. Microbiol. Biotechnol. 105, 7251–7264 (2021).

    Google Scholar 

  47. Pérez-Rubio, P. et al. Extracellular vesicle depletion and UGCG overexpression mitigate the cell density effect in HEK293 cell culture transfection. Mol. Ther. Methods Clin. Dev. 32, 101190 (2024).

    Google Scholar 

  48. Reiter, K. et al. Separation of virus-like particles and extracellular vesicles by flow-through and heparin affinity chromatography. J. Chromatogr. A 1588, 77–84 (2019).

    Google Scholar 

  49. Pereira Aguilar, P. et al. Polymer-grafted chromatography media for the purification of enveloped virus-like particles, exemplified with HIV-1 gag VLP. Vaccine 37, 7070–7080 (2019).

    Google Scholar 

  50. Moleirinho, M. G. et al. Clinical-grade oncolytic adenovirus purification using polysorbate 20 as an alternative for cell lysis. Curr. Gene Ther. 18, 366–374 (2018).

    Google Scholar 

  51. Knezevic, I., Stacey, G. & Petricciani, J. WHO study group on cell substrates for production of biologicals, Geneva, Switzerland, 11–12 June 2007. Biologicals 36, 203–211 (2008).

    Google Scholar 

  52. Ferreira, P. L. et al. Evaluation of novel chromatographic prototypes for supercoiled plasmid DNA polishing. Front. Bioeng. Biotechnol. 11, 1–13 (2023).

    Google Scholar 

  53. Lima, T. M., Souza, M. O. & Castilho, L. R. Purification of flavivirus VLPs by a two-step chomatographic process. Vaccine 37, 7061–7069 (2019).

    Google Scholar 

  54. Al-ghobashy, M. A., Mostafa, M. M., Abed, H. S., Fathalla, F. A. & Salem, M. Y. Correlation between Dynamic Light Scattering and Size Exclusion High Performance Liquid Chromatography for monitoring the effect of pH on stability of biopharmaceuticals Correspondence : Aggregate formation is a major problem affecting both safety and eff. J. Chromatogr. B 1060, 1–9 (2017).

    Google Scholar 

  55. Yang, Y. et al. Size-exclusion HPLC provides a simple, rapid, and versatile alternative method for quality control of vaccines by characterizing the assembly of antigens. Vaccine 33, 1143–1150 (2015).

    Google Scholar 

  56. Díaz-Maneh, A. et al. Targeted knockdown of ATM, ATR, and PDEδ increases Gag HIV-1 VLP production in HEK293 cells. Appl. Microbiol. Biotechnol. 109, 1–18 (2025).

    Google Scholar 

  57. Lavado-García, J., Zhang, T., Cervera, L., Gòdia, F. & Wuhrer, M. Differential N- and O-glycosylation signatures of HIV-1 Gag virus-like particles and coproduced extracellular vesicles. Biotechnol. Bioeng. 119, 1207 (2022).

    Google Scholar 

  58. Yang, O., Prabhu, S. & Ierapetritou, M. Comparison between batch and continuous monoclonal antibody production and economic analysis. Ind. Eng. Chem. Res. 58, 5851–5863 (2019).

    Google Scholar 

Download references

Related Posts